A new 1,4-Dihydropyridine-Based L-/T-Type Calcium Channel Inhibitor, HM12, Provides in Vivo and in silico Cardioprotective Effects in Doxorubicin-Treated Rats
Oluwafemi Ezekiel Kale, Miyase Gözde Gündüz, Ifabunmi Oduyemi Osonuga, Olufunsho Awodele, Martins Ekor
This study evaluates HM12, a calcium channel inhibitor, for cardioprotective effects against doxorubicin toxicity in rats, showing improved antioxidant status and reduced inflammation.
bioRxiv · Sep 21, 2025 · PreprintPharmacology & Toxicology